Adherence Rate to Disease Modifying Anti Rheumatic Drugs in Egyptian Patients With Rheumatoid Arthritis: Possible Predictions and Correlations
试验速览
- 阶段
- 不适用
- 入组人数
- 73
- 主要终点
- Percentage of patients adherent to the treatment through MMAS-8.
研究概览
简要总结
The study aims at determining adherence rate to DMARDS and predicting factors affecting treatment adherence among sample of Egyptian patients with RA.
详细描述
Rheumatoid arthritis (RA) is an autoimmune disease that causes inflammation of the joints. It is chronic disease and often progressive in course and has a strong impact on people's everyday lives.
Disease Modifying Anti-Rheumatic Drugs (DMARDS), such as methotrexate, leflunomide, hydroxychloroquine, and sulfasalazine are the cornerstone of therapy in RA and are invariably used as initial therapy.
These drugs have shown to retard disease progression including joint destruction.
It is believed that adherence to treatment is crucial for successful therapy, however, non-adherence is a substantial problem in patients with chronic rheumatic conditions, including RA.
Previous studies have reported that DMARDS non adherence results in more disease activity, loss of function, and a lower quality of life.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age more than or equal 18 years old.
- •On current diagnosis of RA determined by a Rheumatologist according to 2010 ACR/EULAR classification criteria for RA.
- •On current treatment with one or more of DMARDS from at least 6 months duration.
- •Patients with cognitive level enabling them to interact in the study. -
排除标准
- •Age less than 18 years old.
- •Patients receiving one or more of DMARDS of period less than 6 months.
- •Patients with psychiatric diagnosis other than effective disorder.
- •Patients with associated disability due to neurological disorder or trauma.
- •Patients with major internal organ failure e.g. heart failure, end stage renal disease or hepatic failure.
- •Patients with severe cognitive impairment interfering with the proper communication and interaction within the study process.
结局指标
主要结局
Percentage of patients adherent to the treatment through MMAS-8.
时间窗: 6 months.
The use of Morisky Medication Adherence Scale 8- item (MMAS-8) to determining percentage of patients adherent to treatment.
次要结局
未报告次要终点
研究者
Esraa Moustafa Mohammed
Principal investigator
Assiut University